title: Mifepristone-misoprostol midtrimester abortion: impact of gestational age on the induction-to-abortion interval.
abstract: BACKGROUND
  This study was conducted to explore the effect of gestational age (GA) on the induction-to-abortion interval of mifepristone-misoprostol midtrimester termination of pregnancy (TOP) regimen.
  
  
  METHODS
  This study involved a consecutive series of 270 pregnancies between 12.0 and 22.6 weeks that have undergone legal TOP from April 2006 to June 2009. All women received a single oral dose of 200 mg mifepristone and, 36-48 h later, a course of misoprostol (an initial vaginal dose of 800 mcg plus four oral doses of 400 mcg at 3-hourly intervals). Treatment was considered to be a failure if abortion did not occur within 24 h. The impact of GA, parity and maternal age on the induction-to-abortion interval was assessed by means of Cox regression.
  
  
  RESULTS
  Overall, the mean GA at TOP was 18.0 weeks. The mean induction-to-abortion interval was 9.8 h (SD=8.2 h; range=1-50 h), and 246 women (91%) aborted successfully within 24 h. GA at TOP and parity were the only two variables independently associated with the induction-to-abortion interval. The mean induction-to-abortion interval was increased by about 50% in patients undergoing TOP between 20.0 and 22.6 weeks (12.9 h, SD=8.9), as compared with those at 16.0-19.6 weeks (7.8 h, SD=5.9) and 12.0-15.6 weeks (8.2 h, SD=8.3) (p<.001). The effect of parity on the induction-to-abortion interval was more modest, with a 20% increase in induction-to-abortion interval in nulliparous (10.1 h, SD=9.1), as compared with women with a previous live birth (8.1 h, SD=6.7).
  
  
  CONCLUSIONS
  The mean induction-to-abortion interval increases by 4 h after 20 weeks GA. This information may be relevant for counseling and planning of the procedure.
authors.affiliation: Department of Maternal-Fetal Medicine, ICGON, Hospital Clínic, University of Barcelona and Centre for Biomedical Research on Rare Diseases (CIBERER), 08028 Barcelona, Spain. ogomez@clinic.ub.es
authors.forename: Olga
authors.initials: O
authors.lastname: Gómez
authors.forename: Aina
authors.initials: A
authors.lastname: Borrás
authors.forename: Aintzane
authors.initials: A
authors.lastname: Rabanal
authors.forename: Montse
authors.initials: M
authors.lastname: Palacio
authors.forename: Antonia
authors.initials: A
authors.lastname: Carceller
authors.forename: Oriol
authors.initials: O
authors.lastname: Coll
authors.forename: Eduard
authors.initials: E
authors.lastname: Gratacós
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use; D000021:Abortifacient Agents, Steroidal / Q000627:therapeutic use; D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D005260:Female; D005865:Gestational Age; D006801:Humans; D015735:Mifepristone / Q000627:therapeutic use*; D016595:Misoprostol / Q000627:therapeutic use*; D011247:Pregnancy; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone